Hill Kevin P, Palastro Matthew D, Johnson Brian, Ditre Joseph W
Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, Massachusetts.
Harvard Medical School, Boston, Massachusetts.
Cannabis Cannabinoid Res. 2017 May 1;2(1):96-104. doi: 10.1089/can.2017.0017. eCollection 2017.
Cannabis has been used for medical purposes across the world for centuries. As states and countries implement medical and recreational cannabis policies, increasing numbers of people are using cannabis pharmacotherapy for pain. There is a theoretical rationale for cannabis' efficacy for pain management, although the subjective pain relief from cannabis may not match objective measurements of analgesia. As more patients turn to cannabis for pain relief, there is a need for additional scientific evidence to evaluate this increase. Research for this review was performed in the PubMed/National Library of Medicine database. Preclinical studies demonstrate a narrow therapeutic window for cannabis as pharmacotherapy for pain; the body of clinical evidence for this indication is not as extensive. A recent meta-analysis of clinical trials of cannabis and cannabinoids for pain found modest evidence supporting the use of cannabinoid pharmacotherapy for pain. Recent epidemiological studies have provided initial evidence for a possible reduction in opioid pharmacotherapy for pain as a result of increased implementation of medical cannabis regimens. With increased use of medical cannabis as pharmacotherapy for pain comes a need for comprehensive risk-benefit discussions that take into account cannabis' significant possible side effects. As cannabis use increases in the context of medical and recreational cannabis policies, additional research to support or refute the current evidence base is essential to attempt to answer the questions that so many healthcare professionals and patients are asking.
几个世纪以来,大麻在世界各地一直被用于医疗目的。随着各国和各地区实施医用和娱乐用大麻政策,越来越多的人使用大麻药物疗法来缓解疼痛。大麻对疼痛管理具有疗效,这有其理论依据,尽管大麻带来的主观疼痛缓解可能与镇痛的客观测量结果并不相符。随着越来越多的患者转向使用大麻来缓解疼痛,需要更多科学证据来评估这种增长情况。本综述的研究是在PubMed/国立医学图书馆数据库中进行的。临床前研究表明,大麻作为疼痛药物疗法的治疗窗口较窄;关于这一适应症的临床证据并不那么广泛。最近一项对大麻和大麻素用于疼痛治疗的临床试验的荟萃分析发现,有适度证据支持使用大麻素药物疗法治疗疼痛。最近的流行病学研究提供了初步证据,表明由于医用大麻疗法的实施增加,用于疼痛治疗的阿片类药物疗法可能会减少。随着医用大麻作为疼痛药物疗法的使用增加,需要进行全面的风险效益讨论,要考虑到大麻可能产生的重大副作用。随着在医用和娱乐用大麻政策背景下大麻使用量的增加,开展更多研究以支持或反驳当前的证据基础,对于试图回答众多医疗保健专业人员和患者所提出的问题至关重要。
Cannabis Cannabinoid Res. 2017-5-1
Sports Health. 2020-9-16
Front Pharmacol. 2018-11-13
Cochrane Database Syst Rev. 2018-3-7
Curr Neurol Neurosci Rep. 2018-6-19
Eur Neuropsychopharmacol. 2020-7
J Psychoactive Drugs. 2025-6-10
Front Bioeng Biotechnol. 2025-4-10
Front Psychol. 2016-10-13
Neuroscience. 2016-12-3
Health Aff (Millwood). 2016-7-1
N Engl J Med. 2016-4-21